Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical setting

被引：1

作者：

Fougerousse, A. -C. ^{[1
]}

Maccari, F. ^{[2
]}

Beauchet, A. ^{[3
,4
]}

Parier, J. ^{[2
]}

Boulard, C. ^{[5
]}

Becherel, P. -A. ^{[6
]}

Quiles-Tsimaratos, N. ^{[7
]}

Le Guyadec, T. ^{[8
]}

Thomas-Beaulieu, D. ^{[9
]}

Halioua, B. ^{[10
]}

Begon, E. ^{[11
]}

Bastien, M. ^{[12
]}

Perrot, J. -L. ^{[13
]}

Pallure, V. ^{[14
]}

Bilan, P. ^{[15
]}

Steff, M. ^{[15
]}

Pfister, P. ^{[10
]}

Vermersch-Langlin, A. ^{[16
]}

Boye, T. ^{[17
]}

Mery-Bossard, L. ^{[18
]}

Maillard, H. ^{[19
]}

Kemula, M. ^{[10
]}

Girard, C. ^{[20
]}

Poiraud, C. ^{[21
]}

Monfort, J. -B. ^{[22
]}

Kupfer-Bessaguet, I. ^{[23
]}

Perrussel, M. ^{[24
]}

Lons-Danic, D. ^{[25
]}

Sultan, N. ^{[26
]}

Lorier, E. ^{[10
]}

Zeitoun, M. ^{[27
]}

Wagner, L. ^{[10
]}

Gabison, G. ^{[28
]}

Mahe, E. ^{[29
]}

机构：

[1] Hop Instruct Armees Begin, Dept Dermatol, St Mande, France

[2] Private Off, La Varenne St Hilaire, France

[3] Univ Paris Saclay, CHU Ambroise Pare, AP HP, Dept Publ Hlth, Boulogne, France

[4] Univ Paris Saclay, UVSQ, Boulogne, France

[5] Hop Havre, Dept Dermatol, Montivilliers, France

[6] Hop Prive Antony, Dept Dermatol, Antony, France

[7] Hop St Joseph, Dept Dermatol, Marseille, France

[8] Hop Instruct Armees Percy, Dept Dermatol, Clamart, France

[9] Ctr Hosp Intercommunal Poissy St Germain Laye, Dept Dermatol, Poissy, France

[10] Private Off, Paris, France

[11] Hop Rene Dubos, Dept Dermatol, Pontoise, France

[12] Private Off, Joinville Le Pont, France

[13] CHU St Etienne, Dept Dermatol, St Etienne, France

[14] Ctr Hosp, Dept Dermatol, Perpignan, France

[15] Ctr Hosp Robert Ballanger, Dept Dermatol, Aulnay Sous Bois, France

[16] Ctr Hosp, Dept Dermatol, Valenciennes, France

[17] Hop Instruct Armees St Anne, Dept Dermatol, Toulon, France

[18] Ctr Hosp Francois Quesnay, Dept Dermatol, Mantes La Jolie, France

[19] Ctr Hosp, Dept Dermatol, Le Mans, France

[20] CHU St Eloi, Dept Dermatol, Montpellier, France

[21] Ctr Hosp, Dept Dermatol, La Roche Sur Yon, France

[22] CHU Tenon, Dept Dermatol, Paris, France

[23] Ctr Hosp, Dept Dermatol, Niort, France

[24] Private Off, Auray, France

[25] Hop St Joseph, Dept Dermatol, Paris, France

[26] Ctr Hosp Gabriel Martin, Dept Dermatol, St Paul, France

[27] Private Off, Antony, France

[28] Private Off, St Maurice, France

[29] Hop Victor Dupouy, Dept Dermatol, Argenteuil, France

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷 / 12期

关键词：

EXPERIENCE; SURVIVAL;

D O I：

10.1111/jdv.15804

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：E476 / E478

页数：3

共 50 条

[41] Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting
Cavanaugh, Cristi
Orroth, Kate
Qian, Xi
Kumparatana, Pam
Klyachkin, Yuri
Colgan, Stephen
Cordey, Myriam
JAAD INTERNATIONAL, 2024, 16 : 244 - 251
[42] Use of apremilast for the treatment of plaque psoriasis in a real world setting. The experience of a reference hospital in the Canary Islands
Guimera-Martin-Neda, Francisco
Perez-Robayna, Nuria
Gonzalez-Hernandez, Sorahaya
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB143 - AB143
[43] Real-world experience with apremilast: influence of prior therapy on patient benefit in patients with psoriasis from the APPRECIATE Study
Augustin, M.
Kleyn, C. E.
Radtke, M.
Stahle, M.
Sator, P-G
Conrad, C.
Eyerich, K.
Pinter, A.
Wilsmann-Theis, D.
Peter, R-U
Schneider, J.
Bundy, C.
Morys, S.
Cordey, M.
Koscielny, V
Griffith, C.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 125 - 125
[44] Real-world efficacy of apremilast in patients with moderate plaque psoriasis: Results from the Corrona Psoriasis Registry
Merola, Joseph
Gottlieb, Alice B.
McLean, Robert R.
Cirulli, Joshua
Williams, Catherine
Linowski, Gregory
Litman, Heather J.
Guo, Ning
Emeanuru, Kelechi
Strober, Bruce
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB115 - AB115
[45] REAL WORLD COMPARISON OF PERSISTENCE AND ADHERENCE AMONG BIOLOGIC NAIVE PATIENTS INITIATING APREMILAST OR BIOLOGICS FOR THE TREATMENT OF PSORIASIS IN THE UNITED STATES
Feldman, S. R.
Bonafede, M. M.
Pelletier, C.
Mehta, R.
Brouillette, M.
Smith, D.
Wilson, K. L.
Ni, Q.
VALUE IN HEALTH, 2017, 20 (09) : A566 - A566
[46] TREATMENT OF PSORIASIS: ANALYSIS OF REAL-WORLD EVIDENCE
Karbusicka, M.
Duba, J.
Kolek, M.
VALUE IN HEALTH, 2019, 22 : S911 - S912
[47] Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
Orroth, Kate
Cavanaugh, Cristi
Qian, Xi
Kumparatana, Pam
Klyachkin, Yuri
Colgan, Stephen
Cordey, Myriam
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2334 - 2337
[48] Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
Cetkovska, Petra
Dediol, Iva
Sola, Marija
Kojanova, Martina
Trcko, Katarina
Carija, Antoanela
Ceovic, Romana
Ledic-Drvar, Daniela
Kastelan, Marija
Hrabar, Andina
Missoup, Myriam Cordey
Mamun, Khalid
ADVANCES IN THERAPY, 2023, 40 (04) : 1787 - 1802
[49] Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
Petra Cetkovská
Iva Dediol
Marija Šola
Martina Kojanová
Katarina Trčko
Antoanela Čarija
Romana Čeović
Daniela Ledić-Drvar
Marija Kaštelan
Andina Hrabar
Myriam Cordey Missoup
Khalid Mamun
Advances in Therapy, 2023, 40 (4) : 1787 - 1802
[50] Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
Shah, Bela J.
Mistry, Deval
Chaudhary, Navin
Shah, Shikha
INDIAN DERMATOLOGY ONLINE JOURNAL, 2020, 11 (01) : 51 - 57

← 1 2 3 4 5 →